作者
Chelsea C Pinnix, Andrea K Ng, Bouthaina S Dabaja, Sarah A Milgrom, Jillian R Gunther, C David Fuller, Grace L Smith, Zeinab Abou Yehia, Wei Qiao, Christine F Wogan, Mani Akhtari, Osama Mawlawi, L Jeffrey Medeiros, Hubert H Chuang, William Martin-Doyle, Philippe Armand, Ann S LaCasce, Yasuhiro Oki, Michelle Fanale, Jason Westin, Sattva Neelapu, Loretta Nastoupil
发表日期
2018/6/12
期刊
Blood advances
卷号
2
期号
11
页码范围
1334-1343
出版商
American Society of Hematology
简介
Dose-adjusted rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) has produced good outcomes in primary mediastinal B-cell lymphoma (PMBCL), but predictors of resistance to this treatment are unclear. We investigated whether [18F]fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) findings could identify patients with PMBCL who would not respond completely to DA-R-EPOCH. We performed a retrospective analysis of 65 patients with newly diagnosed stage I to IV PMBCL treated at 2 tertiary cancer centers who had PET-CT scans available before and after frontline therapy with DA-R-EPOCH. Pretreatment variables assessed included metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Optimal cutoff points for progression-free survival (PFS) were determined by a machine learning approach. Univariate and …
学术搜索中的文章
CC Pinnix, AK Ng, BS Dabaja, SA Milgrom, JR Gunther… - Blood advances, 2018